AU784264B2 - Pharmacologically active antiviral peptides and methods of their use - Google Patents

Pharmacologically active antiviral peptides and methods of their use Download PDF

Info

Publication number
AU784264B2
AU784264B2 AU36700/01A AU3670001A AU784264B2 AU 784264 B2 AU784264 B2 AU 784264B2 AU 36700/01 A AU36700/01 A AU 36700/01A AU 3670001 A AU3670001 A AU 3670001A AU 784264 B2 AU784264 B2 AU 784264B2
Authority
AU
Australia
Prior art keywords
seq
antiviral
peptide
value
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36700/01A
Other languages
English (en)
Other versions
AU3670001A (en
Inventor
Curtis Brandt
Hermann Bultmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU3670001A publication Critical patent/AU3670001A/en
Application granted granted Critical
Publication of AU784264B2 publication Critical patent/AU784264B2/en
Priority to AU2006202024A priority Critical patent/AU2006202024B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU36700/01A 2000-02-07 2001-02-06 Pharmacologically active antiviral peptides and methods of their use Ceased AU784264B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006202024A AU2006202024B2 (en) 2000-02-07 2006-05-15 Pharmacologically active antiviral peptides and methods of their use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18082300P 2000-02-07 2000-02-07
US60/180823 2000-02-07
US18405700P 2000-02-22 2000-02-22
US60/184057 2000-02-22
PCT/US2001/003813 WO2001057072A2 (en) 2000-02-07 2001-02-06 Pharmacologically active antiviral peptides and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006202024A Division AU2006202024B2 (en) 2000-02-07 2006-05-15 Pharmacologically active antiviral peptides and methods of their use

Publications (2)

Publication Number Publication Date
AU3670001A AU3670001A (en) 2001-08-14
AU784264B2 true AU784264B2 (en) 2006-03-02

Family

ID=26876670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36700/01A Ceased AU784264B2 (en) 2000-02-07 2001-02-06 Pharmacologically active antiviral peptides and methods of their use

Country Status (9)

Country Link
US (3) US7371809B2 (enExample)
EP (1) EP1272510B1 (enExample)
JP (1) JP4896333B2 (enExample)
AT (1) ATE374208T1 (enExample)
AU (1) AU784264B2 (enExample)
CA (1) CA2399676C (enExample)
DE (1) DE60130641T2 (enExample)
ES (1) ES2293977T3 (enExample)
WO (1) WO2001057072A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293977T3 (es) 2000-02-07 2008-04-01 Wisconsin Alumni Research Foundation Peptidos antivirales farmacologicamente activos y metodo para su uso.
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
US7432045B2 (en) 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
JP4831410B2 (ja) 2006-02-28 2011-12-07 東亞合成株式会社 抗ウイルス性ペプチドおよび抗ウイルス剤
WO2009152518A1 (en) * 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel peptide adjuvant for influenza vaccination
JP2011524373A (ja) 2008-06-13 2011-09-01 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション インフルエンザウイルスに対する新規抗ウイルスペプチド
JP5996190B2 (ja) * 2008-09-19 2016-09-21 ヘンリー フォード ヘルス システムＨｅｎｒｙ Ｆｏｒｄ Ｈｅａｌｔｈ Ｓｙｓｔｅｍ カルパイン阻害のための方法、系および組成物
GB201012651D0 (en) * 2010-07-28 2010-09-15 Univ Edinburgh Peptides
JP6022470B2 (ja) 2010-11-24 2016-11-09 タカラ バイオ ユーエスエー， インコーポレイテッド 分散型タンパク質形質導入ドメインを含む誘導性発現系転写モジュレータおよびその使用方法
US20120190107A1 (en) * 2011-01-26 2012-07-26 Dwayne Bisgrove Enhanced protein transduction
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético
JP7233737B2 (ja) * 2017-05-26 2023-03-07 ビラマティクス スンディリアン ブルハド ペプチドおよび抗ウイルス剤としてのその使用
IL311034A (en) * 2021-08-23 2024-04-01 Amytrx Therapeutics Inc Molecules penetrate leukocytes specifically

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795740A (en) * 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
US4814432A (en) 1987-05-22 1989-03-21 Merck & Co., Inc. Inhibitor of ribonucleotide reductase
US5260420A (en) 1987-07-30 1993-11-09 Centre Regional De Transfusion Sanguine De Lille Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
CA1340682C (en) 1989-07-07 1999-07-27 Pierre Lavallee Antiviral peptides having a 2-oxoalkyl amino acid side chain
IT1231342B (it) 1989-08-28 1991-11-28 Prodotti Antibiotici Spa Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono
JPH0421635A (ja) * 1990-05-16 1992-01-24 Suntory Ltd アセトアルデヒドの毒性抑制剤およびアセトアルデヒドの毒性抑制に有効な飲食物
CA2033447C (en) 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
JPH05310784A (ja) 1991-09-04 1993-11-22 Merck & Co Inc ヒト乳頭腫ウイルスタンパク質と網膜芽細胞腫遺伝子タンパク質との結合のペプチド阻害剤
ATE273035T1 (de) 1993-11-03 2004-08-15 Clarion Pharmaceuticals Inc Hämostatisches pflaster
US5441936A (en) 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
AU3982497A (en) 1996-07-30 1998-02-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner
WO1998047913A2 (en) * 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
AU741546B2 (en) 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
EP1086126A1 (en) 1998-06-10 2001-03-28 The Queen's University of Belfast Cell-permeable peptide
ES2293977T3 (es) 2000-02-07 2008-04-01 Wisconsin Alumni Research Foundation Peptidos antivirales farmacologicamente activos y metodo para su uso.
US7432045B2 (en) 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof

Also Published As

Publication number Publication date
EP1272510B1 (en) 2007-09-26
ES2293977T3 (es) 2008-04-01
CA2399676C (en) 2010-04-06
US8748565B2 (en) 2014-06-10
US20090253624A1 (en) 2009-10-08
CA2399676A1 (en) 2001-08-09
DE60130641T2 (de) 2008-06-26
JP2003522185A (ja) 2003-07-22
DE60130641D1 (de) 2007-11-08
WO2001057072A3 (en) 2002-10-31
WO2001057072A2 (en) 2001-08-09
US8748566B2 (en) 2014-06-10
AU3670001A (en) 2001-08-14
EP1272510A2 (en) 2003-01-08
US20120157376A1 (en) 2012-06-21
ATE374208T1 (de) 2007-10-15
US20050130884A1 (en) 2005-06-16
JP4896333B2 (ja) 2012-03-14
US7371809B2 (en) 2008-05-13

Similar Documents

Publication Publication Date Title
US8748565B2 (en) Pharmacologically active antiviral peptides and methods of their use
Heldwein et al. Entry of herpesviruses into mammalian cells
Bultmann et al. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1
US5633230A (en) Treatment of cytomegalovirus infection
WO2024217209A1 (zh) 冠状病毒多肽类融合抑制剂的长效化的方法
US9221874B2 (en) Antiviral peptides against influenza virus
JP2020536582A (ja) 遺伝子発現抑制剤
US7432045B2 (en) Method of inhibiting influenza infection with antiviral peptides
AU2006202024B2 (en) Pharmacologically active antiviral peptides and methods of their use
KR101260894B1 (ko) 히스티딘을 포함하는 펩타이드 유사체 및 항바이러스제 또는 항암제로서의 이의 용도
CN102574893A (zh) 新的抗致病肽
CA2152373C (en) Treatment of cytomegalovirus infection
EP1862471A2 (en) Pharmacologically active antiviral peptides and methods of their use
US10745448B2 (en) Antiviral peptide and use therefor
US8138146B2 (en) Antiviral peptide and antiviral agent
JP7333538B2 (ja) 抗ウイルス性ペプチドおよびその利用
CN116023439A (zh) 一种抑制新型冠状病毒SARS-CoV-2感染的多肽及其应用
US11767345B2 (en) Antiviral peptide and use thereof

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired